arrow
R

Refujia Gomez

university of california
H指数:22
被引数:6,193

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

742. Intrathecal Autoantibodies in Primary Schizophrenia Spectrum Disorders

742. 原发性精神分裂症谱系障碍患者的鞘内自身抗体

2026-04-250
PRE
Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis

多发性硬化症的髓鞘损伤先于轴突损伤和症状发作

2025-10-200
PRE
High-Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord Pseudoatrophy in Newly Diagnosed Multiple Sclerosis

大剂量脉冲糖皮质激素治疗可预防新诊断多发性硬化患者脊髓白质的假性萎缩

2025-06-240
OAAI
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis

炎性和神经退行性血清蛋白生物标志物可提高对多发性硬化症临床及影像学疾病活动性的检测灵敏度。

2024-05-202
OAAI
An autoantibody signature predictive for multiple sclerosis

多发性硬化症的自身抗体特征预测

2024-04-1912
PRE
Remote Observational Research for Multiple Sclerosis A Natural Experiment

多发性硬化症的远程观察研究是一项自然实验

2023-03-014
OAAI
Reply to Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS
2022-03-260
OA
Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis
2022-01-0468
OAAI
An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis

多发性硬化症的电子,无监督的患者报告的扩展残疾状态量表

2020-11-259
OAAI
Silent progression in disease activity-free relapsing multiple sclerosis
2019-03-30330
OAAI
Harnessing electronic medical records to advance research on multiple sclerosis

利用电子病历推进多发性硬化症的研究

2018-01-0917
PREAI
Long-Term Evolution of Multiple Sclerosis Disability in the Treatment Era
2016-08-13339
OAAI